GlassScriptPhysician profile
Barbee Jan Cunningham
NPI 1891380564
$4,964.64
in general payments reported to CMS, 2019-2025
41 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $1,746 · 2023: $1,091 · 2024: $783 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,009 · Education: $47.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,009.41 |
| Education | $47.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.40 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $443.26 | 2021-2025 | Fasenra, Tezspire, Saphnelo |
| Alexion Pharmaceuticals, INC. | $433.63 | 2024-2025 | Ultomiris |
| Amgen INC. | $362.56 | 2022-2025 | Uplizna, Krystexxa |
| Novo Nordisk INC | $337.15 | 2021-2023 | Ozempic, Rybelsus |
| Tg Therapeutics, INC. | $273.07 | 2025 | |
| Lilly USA, LLC | $201.87 | 2022-2024 | Mounjaro, Kisunla |
| Takeda Pharmaceuticals U.S.A., INC. | $182.98 | 2021-2024 | Trintellix, Gammagard |
| Argenx US, INC. | $172.64 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Ironshore Pharmaceuticals INC. | $158.69 | 2022-2024 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $150.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.57 | 2022-2023 | Jardiance |
| Janssen Biotech, INC. | $131.95 | 2024-2025 | Tremfya |
| Otsuka America Pharmaceutical, INC. | $122.81 | 2022-2023 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $120.22 | 2022-2023 | Freestyle Libre |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbee Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.